Seroatlas · Human Serome Atlas

SMR3A

Submaxillary gland androgen-regulated protein 3A

Also known as: PBI, PRL5, PROL5, SMR3A_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q99954
Gene
SMR3A
Ensembl
ENSG00000109208
Chromosome
4
Canonical length
134 aa
Protein class
Predicted secreted proteins
Secretome location
Secreted to digestive system

OverviewNCBI Gene

Predicted to enable endopeptidase inhibitor activity. Predicted to be involved in regulation of sensory perception of pain. Predicted to be located in extracellular region. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

134 residues, UniProt reviewed canonical sequence.

>Q99954|SMR3A
     1  MKSLTWILGL WALAACFTPG ESQRGPRGPY PPGPLAPPPP PCFPFGTGFV PPPHPPPYGP
    61  GRFPPPLSPP YGPGRIPPSP PPPYGPGRIQ SHSLPPPYGP GYPQPPSQPR PYPPGPPFFP
   121  VNSPTDPALP TPAP

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SMR3A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Secreted
Secreted
Yes
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.65
Highest tissue expression
56 nTPM

Expression across tissuesHPA

Tissue

  • salivary gland: 56 nTPM
  • thyroid gland: 0.9 nTPM
  • prostate: 0.2 nTPM
  • esophagus: 0.1 nTPM
  • adipose tissue: 0 nTPM
  • adrenal gland: 0 nTPM

Single-cell type

  • lacrimal acinar cells: 2,832 nCPM
  • salivary acinar cells: 112 nCPM
  • submucosal glandular cells: 15 nCPM
  • conjunctival goblet cells: 13 nCPM
  • ocular epithelial cells: 9.9 nCPM
  • epididymal efferent duct ciliated cells: 4.2 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • midbrain: 1.2 nTPM
  • thalamus: 0.4 nTPM
  • hypothalamus: 0.1 nTPM
  • amygdala: 0 nTPM
  • basal ganglia: 0 nTPM
  • cerebellum: 0 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.73
gnomAD pLI
0.39
gnomAD missense Z
-0.59
DepMap mean gene effect
0.02
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SMR3A as an antibody target. Whether an autoantibody or antibody against SMR3A could matter depends on whether native SMR3A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SMR3A is annotated as secreted, so native SMR3A circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label SMR3A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SMR3A. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...